Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Reviewed By Analysts

Agios Pharmaceuticals

Agios Pharmaceuticals

Its quick ratio for most recent quarter is 6.30 along with current ratio for most recent quarter of 6.30.

The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share repurchases and debt reduction. Canada Pension Plan Investment Board increased its position in Agios Pharmaceuticals by 31.8% in the third quarter. (AGIO). These ratios are important while doing valuation of the company or the shares of the company. (NASDAQ:AGIO). Free cash flow represents the amount of cash that a company has generated for shareholders after paying off expenses and investing in growth. (AGIO) reported its EPS in the last quarter as $-1.34/Share beating the analyst estimate of $-1.51/Share by the difference of $0.17. TIAA CREF Investment Management LLC now owns 84,412 shares of the biopharmaceutical company's stock worth $4,459,000 after buying an additional 3,636 shares in the last quarter. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

08/08/2016 - Agios Pharmaceuticals, Inc. had its " rating reiterated by analysts at Goldman Sachs. On Tuesday, February 21 NELSEN ROBERT sold $6.68 million worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) or 135,364 shares.

Agios Pharmaceuticals (NASDAQ:AGIO) has insider ownership of 10.55% and institutional ownership of 88.79%. The firm's market cap is $2.13 billion. Agios Pharmaceuticals has recorded a 50-day average of $53.56 and a two hundred day average of $50.53.

According to sentiments of 9 analysts the mean estimates of short term price target for the company's stock is marked at $62.89. This showed the surprise of 13.6% in the last quarter earnings. They expect $-1.83 EPS, down 200.00% or $1.22 from last year's $-0.61 per share. The company's year to date (YTD) performance is at 20.68%. The stock has earnings growth of -24.30% yoy and showed a high EPS growth of 10.60% over the past five years. Analysts forecast that Agios Pharmaceuticals Inc will post ($7.31) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and global copyright laws.

08/19/2016 - BTIG Research began new coverage on Agios Pharmaceuticals, Inc. giving the company a "neutral" rating. The stock has "Buy" rating by SunTrust on Wednesday, March 30. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has a Return on Assets (ROA) of -35.40%.

Investors may be interested in viewing the Gross Margin score on shares of Agios Pharmaceuticals, Inc. They now have a Dollars 75 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of "Buy" and a consensus target price of $63.54. The shares were sold at an average price of $55.00, for a total value of $354,090.00. Insiders now own 0.50% of total outstanding shares. About 758,153 shares traded or 77.09% up from the average. The number of shares now owned by investors are 42.23 mln. The disclosure for this sale can be found here.

The company declined -3.22% and closed its last trading session at $50.36.

Agios Pharmaceuticals, a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Recommended News

  • Jeremy Corbyn says election is not a 'foregone conclusion'

    Jeremy Corbyn says election is not a 'foregone conclusion'

    In her first campaign visit, to a Labour marginal in Bolton, the Prime Minister told an invited audience: "There's a very clear choice at this election".
    Naked mole-rats can survive near-suffocation

    Naked mole-rats can survive near-suffocation

    North American freshwater turtles and goldfish, for example, spend their winters in oxygen-lacking, ice-covered lakes and ponds. With all those rodents breathing and clogging up burrows, they often encounter low-oxygen and high-carbon dioxide conditions.
    Sean Payton testifies at Cardell Hayes' sentencing

    Sean Payton testifies at Cardell Hayes' sentencing

    Saints Head Coach Sean Payton testified about Smith's character and described him as an extremely smart, passionate man. Hayes' defense said after the trial that Smith's popularity led to a rush to judgment by police and prosecutors.
  • FA Youth Cup: Chelsea, Man City draw 1-1

    Manchester City had to work hard for their Wembley appearance after a narrow 1-0 win over a determined if limited Liverpool side. Foden fired in the equaliser to leave the tie finely poised ahead of next Wednesday's second leg at Stamford Bridge.
    Pakistan's top court rules prime minister can stay in power

    Pakistan's top court rules prime minister can stay in power

    Pakistan's stock market jumped after the decision, with the Karachi Stock Exchange's benchmark KSE100 gaining nearly 2 percent. Reports said the joint investigation team will consist of members of Pakistan's Inter-Services Intelligence (ISI).

    Sweet drinks linked to dementia

    Having at least one diet drink a day increased the risk compared to consuming less than one diet drink a week, a study found. They were also examined using MRIs (magnetic resonance imaging) and cognitive testing to measure their thinking and memory.
  • USA 'ready to help bring' Syria conflict to end: Haley

    The civil war is separate from the US -led effort against the Islamic State group in the north of the country. He gave the order to fire missiles at Syria to punish Moscow's ally for its suspected use of poison gas.
    Contraceptive pills are 'making women miserable', study finds

    Contraceptive pills are 'making women miserable', study finds

    Researchers discovered that the women who took the real pills felt different, as compared to those who received a placebo. He said: 'This might in some cases be a contributing cause of low compliance and irregular use of contraceptive pills.
    Premier Wall asks Education Minister Morgan 'to review the library funding issue'

    Premier Wall asks Education Minister Morgan 'to review the library funding issue'

    Replying to a question in the legislature last month, Morgan appeared to suggest there were too many libraries in the province. According to the provincial government, tough decisions had to be made to keep the economy strong.
  • Arkansas court allows state to use execution drug

    Arkansas court allows state to use execution drug

    The Arkansas Supreme Court said in a 4-3 ruling that it would not reconsider its decision to stay Johnson's execution. Johnson and Ledell Lee, the other prisoner who was scheduled to be executed tonight, both say they are innocent.

    US House panel to hold hearing on consumer airline issues

    No witnesses or precise date was announced, but the hearing comes after a drumbeat of concern from members of Congress. Munoz said that the response to a letter that the CEO sent to a group of United's "most loyal customers" was positive.

    Stock Floundering in Session: GNC Holdings, Inc. (NYSE:GNC)

    The institutional investor owned 584,659 shares of the company's stock after buying an additional 72,650 shares during the period. The specialty retailer reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.04.

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.